公开(公告)号：US09006387B2

公开(公告)日：2015-04-14

申请号：US14180886

申请日：2014-02-14

Applicant: AbbVie, Inc.

Inventor： Rolf Wagner ,  John K. Pratt ,  Dachun Liu ,  Michael D. Tufano ,  David A. DeGoey ,  Warren M. Kati ,  Charles W. Hutchins ,  Pamela L. Donner ,  John T. Randolph ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  Mark A. Matulenko ,  Ryan G. Keddy ,  Tammie K. Jinkerson ,  Todd W. Rockway ,  Clarence J. Maring ,  Douglas K. Hutchinson ,  Charles A. Flentge ,  David A. Betebenner ,  Kathy Sarris ,  Kevin R. Woller ,  Seble H. Wagaw ,  Jean C. Califano ,  Wenke Li ,  Daniel D. Caspi ,  Mary E. Bellizzi ,  Yi Gao ,  Allan C. Krueger

IPC: C07K16/00 ,  A61K38/00 ,  C07K5/06 ,  C07D401/14 ,  C07D403/14 ,  C07D417/14 ,  C07C33/26 ,  C07C205/19

CPC classification number: C07F9/65583 ,  C07C33/26 ,  C07C201/06 ,  C07C205/19 ,  C07D207/08 ,  C07D207/09 ,  C07D207/16 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D471/04 ,  C07D491/113 ,  C07K5/06

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20150087618A1

公开(公告)日：2015-03-26

申请号：US14558318

申请日：2014-12-02

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: C07F7/02 ,  C07D405/14 ,  C07D403/14 ,  C07D401/14 ,  C07D413/14

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20250122160A1

公开(公告)日：2025-04-17

申请号：US18647757

申请日：2024-04-26

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Philip R. Kym ,  Jennifer M. Frost ,  Christos Economou ,  Andrew Bogdan ,  Stacy Fosu ,  Zhaoming Xiong ,  Spencer O. Scholz ,  Eric Allan Voight ,  Elliot P. Farney ,  Mark A. Matulenko ,  Matthew J. O'Connor ,  Christina Baumgartner ,  Qingwei Zhang ,  Reza Shiroodi ,  Jason R. Abbott ,  Geoff T. Halvorsen

IPC: C07D285/06 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/501 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

公开(公告)号：US20230285378A1

公开(公告)日：2023-09-14

申请号：US17941090

申请日：2022-09-09

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Warren M. Kati ,  Tammie K. Jinkerson ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/454 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07D403/14 ,  C07F7/02 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  A61K31/435

CPC classification number: A61K31/454 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07D403/14 ,  C07F7/02 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  A61K31/435 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US09969693B2

公开(公告)日：2018-05-15

申请号：US15239554

申请日：2016-08-17

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC: C07D215/48 ,  C07D401/12 ,  C07D409/14 ,  C07D487/08 ,  C07D401/14 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20170157105A1

公开(公告)日：2017-06-08

申请号：US15434789

申请日：2017-02-16

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/695

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20150218102A1

公开(公告)日：2015-08-06

申请号：US14613579

申请日：2015-02-04

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC: C07D215/48 ,  C07D409/14 ,  C07D487/08 ,  C07D471/04 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract translation: 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2和R3如本说明书中所定义，可用于治疗由电压门控钠预防或改善的病症或病症 通道，例如Nav1.7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。